This study investigates the reprogramming of myeloid cells in patients with thyroid carcinoma. The investigators hypothesize that tumor-derived factors change the function of myeloid cells (peripheral blood and bone marrow-derived) in such a way that these immune cells promote tumor growth rather than combat the tumor.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Group 1:
Subject is newly diagnosed with TC, therapy-naive and is planned to receive conventional treatment by surgery followed by RAI; no evidence of local or distant metastases
* Group 2:
Subject has TC with evidence of distant metastases (either newly diagnosed or therapy-naive or patients with persistent or recurrent disease); at least 4 months since the previous treatment with RAI if applicable
* Group 3:
Subject is diagnosed with MNG, is euthyroid, and is planned to undergo surgery - Group 4: Subject is diagnosed with MNG, is euthyroid, and is planned to receive RAI treatment
\- Group 5: Healthy individuals who are euthyroid and have no evidence of thyroid disease
Exclusion Criteria:
* Mentally incompetent
* Pregnant, trying to become pregnant or breastfeeding
* Known inflammatory or infectious diseases or an immunosuppressive status
* Using medication interfering with the immune system
* Reduced platelet counts or other conditions associated with an increased risk of bleeding
* Severe comorbidities: other active malignancy (except for basal cell carcinoma)
* Serious psychiatric pathology
* A self-reported alcohol consumption of \>21 units per week